Band 3
Provided by Joseph Basile
Joe Basile provides strategic advice to Boards and C-suite executives, representing clients in their most challenging situations and transactional matters.
Joe’s practice focuses on mergers and acquisitions. He has especially deep experience in cross-border transactions, with an extensive body of work that includes mergers, acquisitions, divestitures, control and minority investments, joint ventures, and strategic alliances involving parties across North America, Europe, Asia, and Latin America. Alongside Joe’s cross-border practice, he maintains a robust domestic U.S. practice that includes unsolicited and negotiated public company, private company, and distressed M&A transactions.
Joe has served as a Vice Chair of the International M&A and Joint Ventures Committee of the ABA Section of International Law and was a member of the International Bar Association. He is also the author of numerous articles and a frequent speaker and panelist on M&A, shareholder activism and corporate governance.
Joe is also actively involved in non-profit and civic affairs. He is a member of the Massachusetts Business Roundtable, currently serving as a member of the Executive Committee of the MBR’s Board of Directors. In addition, Joe is a member of the National Association of Corporate Directors. He has also served as a member of the Board of Trustees of Stonehill College and the Massachusetts State Ethics Commission.
Education: Stonehill College, AB, summa cum laude; Harvard Law School, JD, cum laude
Provided by Chambers
Joseph Basile draws from a wealth of experience to counsel clients on corporate law matters and M&A matters. His practice sees him handle cross-border transactions, bankruptcy M&A and joint venture work.
Provided by Chambers
"Joseph is highly experienced and knowledgable."
"Joseph is highly experienced and knowledgable."
1 item provided by Hogan Lovells US LLP
Thermo Fisher Acquisition of Brammer Bio
Foley Hoag recently represented Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, in its $1.7 billion acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies.
Thermo Fisher Acquisition of Brammer Bio
Foley Hoag recently represented Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, in its $1.7 billion acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies.
